S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
US Dollar Replaced By "Biden Bucks"? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
US Dollar Replaced By "Biden Bucks"? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
US Dollar Replaced By "Biden Bucks"? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
US Dollar Replaced By "Biden Bucks"? (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NASDAQ:MRKR

Marker Therapeutics - MRKR Earnings Date, Estimates & Call Transcripts

$0.39
-0.05 (-11.27%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.38
$0.46
50-Day Range
$0.26
$0.56
52-Week Range
$0.25
$2.05
Volume
979,438 shs
Average Volume
4.93 million shs
Market Capitalization
$32.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.25

Earnings Summary

Upcoming
Earnings Date
Nov. 9Estimated
Actual EPS
(May. 13)
-$0.12 Beat By $0.01
Consensus EPS
(May. 13)
-$0.13
Last Year's Q2 EPS
(5/12/2021)
-$0.16
Skip Charts & View Estimated and Actual Earnings Data

MRKR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRKR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Marker Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.12)($0.12)($0.12)
Q2 20222($0.13)($0.11)($0.12)
Q3 20222($0.12)($0.11)($0.12)
Q4 20222($0.12)($0.08)($0.10)
FY 20227($0.49)($0.42)($0.46)
Q1 20231($0.12)($0.12)($0.12)
Q2 20231($0.13)($0.13)($0.13)
Q3 20231($0.14)($0.14)($0.14)
Q4 20231($0.14)($0.14)($0.14)
FY 20234($0.53)($0.53)($0.53)

MRKR Earnings Date and Information

Marker Therapeutics last issued its quarterly earnings results on May 13th, 2022. The reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. The company had revenue of $0.96 million for the quarter. Marker Therapeutics has generated ($0.50) earnings per share over the last year (($0.50) diluted earnings per share). Earnings for Marker Therapeutics are expected to grow in the coming year, from ($0.42) to ($0.41) per share. Marker Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 9th, 2022 based off prior year's report dates.

Marker Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/9/2022
(Estimated)
        
5/13/2022Q1 2022($0.13)($0.12)+$0.01($0.12)$0.96 million
3/17/2022Q4 2021($0.12)($0.12)($0.12)$1.24 million
11/10/20219/30/2021($0.13)($0.12)+$0.01($0.09)
8/10/20216/30/2021($0.12)($0.13)($0.01)($0.13)
5/12/20213/31/2021($0.16)($0.16)($0.16)  
3/8/202112/31/2020($0.16)($0.18)($0.02)($0.18)
11/9/20209/30/2020($0.15)($0.16)($0.01)($0.16)  
8/10/20206/30/2020($0.14)($0.14)($0.14)$0.47 million
5/11/20203/31/2020($0.11)($0.14)($0.03)($0.14)  
3/12/2020Q4 2019($0.1260)($0.1111)+$0.0149($0.11)$0.21 million
11/12/2019Q3($0.13)($0.12)+$0.01($0.12)  
8/8/2019Q2 2019($0.1280)($0.12)+$0.0080($0.12)
5/9/2019Q1($0.17)($0.12)+$0.05($0.12)$0.06 million
3/15/2019Q4 2018($0.21)($0.64)($0.43)$5.44
11/13/2018Q3 2018($0.44)($0.32)+$0.12($0.32)
8/9/2018Q2 2018($0.41)($0.41)($0.41)$0.21 million
5/15/2018Q1 2018($0.30)($0.30)($0.30)
3/23/2018Q4 2017($0.25)($0.25)($0.25)
11/15/2017Q3 2017($0.39)($0.39)($0.39)
8/7/2017Q2 2017($0.22)($0.22)($0.22)
5/5/2017Q1 2017($0.29)($0.29)($0.29)
3/14/2017Q4 2016($0.18)($0.18)($0.18)
11/4/2016Q3 2016($0.29)($0.29)($0.29)
8/15/2016Q2 2016$0.36+$0.36$0.36
5/16/2016Q1 2016($0.84)($0.84)($0.84)












Marker Therapeutics Earnings - Frequently Asked Questions

When is Marker Therapeutics's earnings date?

Marker Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 9th, 2022 based off last year's report dates. Learn more on MRKR's earnings history.

Did Marker Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Marker Therapeutics (NASDAQ:MRKR) reported ($0.12) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.13) by $0.01. Learn more on analysts' earnings estimate vs. MRKR's actual earnings.

How much revenue does Marker Therapeutics generate each year?

Marker Therapeutics (NASDAQ:MRKR) has a recorded annual revenue of $1.24 million.

How much profit does Marker Therapeutics generate each year?

Marker Therapeutics (NASDAQ:MRKR) has a recorded net income of -$41.88 million. MRKR has generated -$0.50 earnings per share over the last four quarters.

What is Marker Therapeutics's EPS forecast for next year?

Marker Therapeutics's earnings are expected to grow from ($0.42) per share to ($0.41) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:MRKR) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.